Short Interest in Bluejay Diagnostics, Inc. (NASDAQ:BJDX) Rises By 298.5%

Bluejay Diagnostics, Inc. (NASDAQ:BJDX) was the recipient of a significant growth in short interest in December. As of December 15th, there was short interest totalling 27,100 shares, a growth of 298.5% from the November 30th total of 6,800 shares. Based on an average daily trading volume, of 617,400 shares, the short-interest ratio is presently 0.0 days. Currently, 4.9% of the company’s stock are sold short.

Hedge Funds Weigh In On Bluejay Diagnostics

A hedge fund recently bought a new stake in Bluejay Diagnostics stock. CVI Holdings LLC bought a new stake in Bluejay Diagnostics, Inc. (NASDAQ:BJDX) during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 66,165 shares of the company’s stock, valued at approximately $46,000. CVI Holdings LLC owned approximately 19.69% of Bluejay Diagnostics as of its most recent SEC filing. 18.47% of the stock is owned by institutional investors.

Bluejay Diagnostics Price Performance

Shares of NASDAQ BJDX traded down $0.10 during mid-day trading on Thursday, reaching $3.70. 23,601 shares of the company’s stock traded hands, compared to its average volume of 172,258. The business has a 50-day simple moving average of $4.35 and a 200 day simple moving average of $25.64. The stock has a market cap of $2.05 million, a P/E ratio of 0.00 and a beta of 0.70. Bluejay Diagnostics has a 1-year low of $3.03 and a 1-year high of $992.00.

Bluejay Diagnostics Company Profile

Bluejay Diagnostics, Inc, a medical diagnostic company, develops rapid test for the monitoring of disease progression in the United States. It is developing Symphony platform, a technology platform comprising Symphony analyzer that orchestrates blood processing, biomarker isolation, and immunoassay preparation using non-contact centrifugal force; and Symphony Cartridge, which includes reagents and components.